<DOC>
	<DOCNO>NCT01977378</DOCNO>
	<brief_summary>A multicenter , 10-week study evaluate efficacy safety Sustained-Release Desvenlafaxine Hydrochloride versus Sustained-Release venlafaxine Hydrochloride adult major depressive disorder .</brief_summary>
	<brief_title>A Study Sustained-Release Desvenlafaxine Hydrochloride Treatment Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Adult primary diagnosis Major Depressive Disorder Aged 18 year 65 year A primary diagnosis Major Depressive Disorder base criterion Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSM IVTR ) , single recurrent episode , without psychotic feature Hamilton Psychiatric Rating Scale Depression ( HAMD 17 ) total score ≧ 20 Clinical Global Impressions ScaleSeverity ( CGIS ) score ≧4 Known hypersensitivity desvenlafaxine venlafaxine Significant risk suicide base clinical judgment Women pregnant , breastfeeding , plan become pregnant study Had history seizure disorder History current evidence gastrointestinal disease know interfere absorption excretion drug history surgery know interfere absorption excretion drug Any unstable hepatic , renal , pulmonary , cardiovascular , ophthalmologic , neurologic , severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result Cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>